Thrombolysis with alteplase after stroke: extending outcomes
نویسندگان
چکیده
منابع مشابه
Thrombolysis with alteplase after stroke: extending outcomes
1 Ali R, Nicholas RS, Muraro PA. Drugs in development for relapsing multiple sclerosis. Drugs 2013; published online April 23. DOI:10.1007/s40265-0130030-6. 2 Barkhof F, Simon JH, Fazekas F, et al. MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nat Rev Neurol 2011; 8: 13–21. 3 Sormani MP, Bonzano L, Roccatagliata L, et al. Magnetic resonance imaging as a potentia...
متن کاملThrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study.
BACKGROUND Intravenous alteplase is approved for use within 3 h of ischaemic stroke onset, although a meta-analysis of randomised controlled trials suggests treatment benefit up to 4.5 h. We compared outcome in patients treated between 3 h and 4.5 h versus those treated within 3 h, who were recorded in the in the Safe Implementation of Treatments in Stroke (SITS), a prospective internet-based a...
متن کاملThrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
BACKGROUND Intravenous thrombolysis with alteplase is the only approved treatment for acute ischemic stroke, but its efficacy and safety when administered more than 3 hours after the onset of symptoms have not been established. We tested the efficacy and safety of alteplase administered between 3 and 4.5 hours after the onset of a stroke. METHODS After exclusion of patients with a brain hemor...
متن کاملCost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke.
BACKGROUND AND PURPOSE The aim of this study was to assess the costs and cost-effectiveness of intravenous thrombolysis treatment with alteplase (Actilyse) of acute ischemic stroke with 24-hour in-house neurology coverage and use of magnetic resonance imaging. METHODS A health economic model was designed to calculate the marginal cost-effectiveness ratios for time spans of 1, 2, 3 and 30 year...
متن کاملDRUG PROFILE Alteplase: thrombolysis for acute ischemic stroke
10.1586/14750708.2.5.709 © 2 Alteplase is the only licensed thrombolytic agent for the treatment of acute ischemic stroke. The body of evidence to date suggests that it reduces the number of stroke patients who are dead or dependent at follow up, despite the risk of intracranial hemorrhage. However, in Europe, the license has only been granted for people aged under 80 years who fulfil specific ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Lancet Neurology
سال: 2013
ISSN: 1474-4422
DOI: 10.1016/s1474-4422(13)70149-2